| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2006 | CA2583783A1 Complex containing mequitazine, a cyclodextrin and an interaction agent |
| 04/27/2006 | CA2583710A1 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 04/27/2006 | CA2583667A1 Sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 04/27/2006 | CA2583622A1 Ophthalmic compositions for treating ocular hypertension |
| 04/27/2006 | CA2583593A1 Ophthalmic compositions for treating ocular hypertension |
| 04/27/2006 | CA2583576A1 Chimera (double) decoy |
| 04/27/2006 | CA2583565A1 3,6-substituted 5-arylamino-1h-pyridine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease causedby necrosis or apoptosis |
| 04/27/2006 | CA2583548A1 Phosphate binder with reduced pill burden |
| 04/27/2006 | CA2583536A1 Cgrp receptor antagonists |
| 04/27/2006 | CA2583534A1 Cgrp receptor antagonists |
| 04/27/2006 | CA2583454A1 Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 04/27/2006 | CA2583392A1 Imidazole derivatives as vanilloid receptor ligands |
| 04/27/2006 | CA2583373A1 Self-gelling alginate systems and uses thereof |
| 04/27/2006 | CA2583363A1 Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells |
| 04/27/2006 | CA2583342A1 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease |
| 04/27/2006 | CA2583267A1 Novel b1 bradykinin receptor antagonists |
| 04/27/2006 | CA2583185A1 Use of a2a adenosine receptor agonists |
| 04/27/2006 | CA2583177A1 Compounds for nonsense suppression, and methods for their use |
| 04/27/2006 | CA2583158A1 Triazoles and their use as bradykinin b1 receptor antagonists |
| 04/27/2006 | CA2583153A1 1,5-diheterocycle-1h-triazole derivative |
| 04/27/2006 | CA2583152A1 Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
| 04/27/2006 | CA2583138A1 Process for producing natural immunobiotic extract and uses thereof |
| 04/27/2006 | CA2583115A1 Hydroalcoholic extract of erythrina mulungu, pharmaceutical compositions and processes for producing these substances |
| 04/27/2006 | CA2582885A1 Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| 04/27/2006 | CA2582778A1 Pyridine derivatives and the preparation and the therapeutic use thereof |
| 04/27/2006 | CA2582464A1 Antisense modulation of ptp1b expression |
| 04/27/2006 | CA2582163A1 Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| 04/27/2006 | CA2581745A1 Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
| 04/27/2006 | CA2581723A1 Process for preparing telmisartan |
| 04/27/2006 | CA2581303A1 Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent |
| 04/27/2006 | CA2581278A1 Methods and materials for the inhibition of transplant rejection |
| 04/27/2006 | CA2580976A1 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
| 04/27/2006 | CA2580913A1 N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| 04/27/2006 | CA2580170A1 Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| 04/27/2006 | CA2578300A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 04/27/2006 | CA2576643A1 Screening assays for inhibitors of a staphylococcus aureus siderophore |
| 04/27/2006 | CA2574518A1 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 04/26/2006 | EP1650312A2 Functional assay of high-density lipoprotein |
| 04/26/2006 | EP1650266A1 Product of coprecipitation of sparingly soluble substance and water-soluble polymer and process for producing the same |
| 04/26/2006 | EP1650221A2 Novel compounds |
| 04/26/2006 | EP1650218A1 The artificial cpg single strand deoxidation oligonucleotide and its antiviral uses |
| 04/26/2006 | EP1650210A1 Therapeutic agent for hyperpotassemia and bone disease |
| 04/26/2006 | EP1650209A1 Griseusin derivatives and their use as antitumor agents |
| 04/26/2006 | EP1650206A1 Phenylazole compounds, production process, and antioxidants |
| 04/26/2006 | EP1650204A1 Process for producing 1,2,4-triazole compound and intermediate therefor |
| 04/26/2006 | EP1650203A1 Process of preparation of benzimidazol-2-yl quinolinone derivatives |
| 04/26/2006 | EP1650202A1 4,5-DIHYDRONAPHTHO [1,2-b] THIOPHENE DERIVATIVE |
| 04/26/2006 | EP1650199A1 Sulfonamide derivative having isoxazole ring |
| 04/26/2006 | EP1650195A1 Method of inhibiting production of osteopontin |
| 04/26/2006 | EP1650193A2 6-Phenylphenanthridines with PDE-IV inhibiting activity |
| 04/26/2006 | EP1650192A1 Quinolone derivative or salt thereof |
| 04/26/2006 | EP1650190A1 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same |
| 04/26/2006 | EP1650189A1 Benzylamine derivative |
| 04/26/2006 | EP1650188A1 Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents |
| 04/26/2006 | EP1650186A1 Novel dicarboxylic acid derivatives |
| 04/26/2006 | EP1650183A1 (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
| 04/26/2006 | EP1649871A1 Retroviral protease inhibitor combinations |
| 04/26/2006 | EP1649868A1 IL-12 as an adjuvant for Bordetella pertussis vaccines |
| 04/26/2006 | EP1649860A1 Pharmaceutical composition for ophthalmic use |
| 04/26/2006 | EP1649859A1 Pharmaceutical compositions comprising at least one poorly diffusible anticancer drug and a olidodeoxynucleotide immunestimulant |
| 04/26/2006 | EP1649858A1 Method of preparing an aqueous meloxicam solution and aqueous solution thus produced |
| 04/26/2006 | EP1649857A2 New use of glutamate antagonists for the treatment of cancer |
| 04/26/2006 | EP1649856A2 Use of pimecrolimus for selective immunomodulation |
| 04/26/2006 | EP1649855A1 Medicinal composition |
| 04/26/2006 | EP1649854A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 04/26/2006 | EP1649853A2 Microtubule stabilizing agents for treating atherosclerosis or restenosis |
| 04/26/2006 | EP1649851A2 Pregelatinized starch in a controlled release formulation |
| 04/26/2006 | EP1649850A1 Preparation of biodegradable microparticles containing a biologically active agent |
| 04/26/2006 | EP1649849A2 Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. |
| 04/26/2006 | EP1649761A1 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves |
| 04/26/2006 | EP1649286A2 Improved aminodextran compositions and conjugates and methods of making and using them |
| 04/26/2006 | EP1649283A2 Method for measuring aromatase activity |
| 04/26/2006 | EP1649054A1 Method for diagnosing colorectal cancers |
| 04/26/2006 | EP1649018A2 Sp1 and sp3 targeted cancer therapies and therapeutics |
| 04/26/2006 | EP1649017A1 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer |
| 04/26/2006 | EP1648997A2 Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences |
| 04/26/2006 | EP1648948A1 Thermosensitive polymers for therapeutic use and methods of preparation |
| 04/26/2006 | EP1648942A2 Complex matrix for biomedical use |
| 04/26/2006 | EP1648941A1 Method of processing seaweed |
| 04/26/2006 | EP1648916A1 Method for obtaining a natural mixture of conjugated equine estrogens |
| 04/26/2006 | EP1648915A1 Steroid derivatives and use thereof as medicaments |
| 04/26/2006 | EP1648910A2 Antisense modulation of stearoyl-coa desaturase expression |
| 04/26/2006 | EP1648900A2 Phosphorus-containing macrocycles |
| 04/26/2006 | EP1648897A1 N- [3-(3-substituted-pyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-sulfonamides, and compositions, and methods related thereto |
| 04/26/2006 | EP1648896A1 7-substituted 3-nitro-pyrazolo [1,5-a] pyrimidines |
| 04/26/2006 | EP1648891A1 Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands |
| 04/26/2006 | EP1648888A1 N-(heterobicycloalkanes)-substituted indoles or heteroderivatives thereof |
| 04/26/2006 | EP1648886A1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments |
| 04/26/2006 | EP1648885A1 Novel compounds |
| 04/26/2006 | EP1648884A2 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 04/26/2006 | EP1648882A1 3-fluoro-piperidines as nmda/nr2b antagonists |
| 04/26/2006 | EP1648879A1 Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| 04/26/2006 | EP1648878A1 Piperidine compounds and pharmaceutical compositions containing them |
| 04/26/2006 | EP1648876A1 5-ht sb 2b /sb receptor antagonists |
| 04/26/2006 | EP1648874A2 Piperazine derivatives and their use as therapeutic agents |
| 04/26/2006 | EP1648873A2 Neuroprotective macrocylic compounds and methods for their use |
| 04/26/2006 | EP1648862A2 Substituted arylthiourea derivatives useful as inhibitors of viral replication |
| 04/26/2006 | EP1648855A2 Levalbuterol hydrochloride polymorph a |
| 04/26/2006 | EP1648848A2 Polymorphs of butylated hydroxy anisole |
| 04/26/2006 | EP1648567A1 Perinatal hypoxic-ischemic brain damage treatment |